Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

被引：1
|
作者：
Duvic, M.
Vanaclocha, F.
Bernengo, M. G.
Okada, C.
Breneman, D.
Zinzani, P. L.
Zhang, L.
Bopp, K.
Laird, G.
Hirawat, S.
Prince, M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Turin, Turin, Italy
[3] Portland VA Med Ctr, Portland, OR USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Ist Ematol Oncol Med, Bologna, Italy
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8555
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).
    Duvic, Madeleine
    Becker, Juergen C.
    Dalle, Stephane
    Vanaclocha, Francisco
    Bernengo, Maria Grazia
    Lebbe, Celeste
    Dummer, Reinhard
    Hirawat, Samit
    Zhang, Lei
    Marshood, Miriam
    Laird, Glen
    Prince, H. Miles
    BLOOD, 2008, 112 (11) : 370 - 370
  • [2] A PHASE II INTERNATIONAL, MULTICENTER STUDY OF ORAL PANOBINOSTAT (LBH589) IN PATIENTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
    Bernengo, M. G.
    Vanaclocha, F.
    Duvic, M.
    Kuzel, T.
    Kerdel, F.
    Pinter-Brown, L.
    Bosly, A.
    Okada, C.
    Breneman, D.
    Zinzani, P. L.
    Becker, J.
    Hughey, L.
    Ardaiz, M.
    Zain, J.
    Zhang, L.
    Hirawat, S.
    Laird, G.
    Johnson, D.
    Prince, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 109 - 109
  • [3] Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
    Prince, H. Miles
    Bishton, Mark J.
    Johnstone, Ricky W.
    FUTURE ONCOLOGY, 2009, 5 (05) : 601 - 612
  • [4] Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.
    Ottmann, Oliver G.
    Spencer, Andrew
    Prince, H. Miles
    Bhalla, Kapil N.
    Fischer, Thomas
    Liu, Angela
    Parker, Kathryn
    Jalaluddin, Muhammad
    Laird, Glen
    Woo, Margaret
    Scott, Jeffrey W.
    DeAngelo, Daniel J.
    BLOOD, 2008, 112 (11) : 352 - 353
  • [5] Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
    Dickinson, Michael
    Ritchie, David
    DeAngelo, Daniel J.
    Spencer, Andrew
    Ottmann, Oliver G.
    Fischer, Thomas
    Bhalla, Kapil N.
    Liu, Angela
    Parker, Katie
    Scott, Jeffrey W.
    Bishton, Mark
    Prince, H. Miles
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 97 - 101
  • [6] Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance
    Shao, Wenlin
    Growney, Joseph D.
    Feng, Yun
    O'Connor, Gregory
    Pu, Minying
    Zhu, Wenjing
    Yao, Yung-Mae
    Kwon, Paul
    Fawell, Stephen
    Atadja, Peter
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (09) : 2199 - 2208
  • [7] Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis
    Mascarenhas, John
    Mercado, Alice
    Rodriguez, Amelyn
    Lu, Min
    Kalvin, Carla
    Li, Xiaochun
    Petersen, Bruce
    Najfeld, Vesna
    Goldberg, Judith D.
    Hoffman, Ronald
    BLOOD, 2011, 118 (21) : 361 - 361
  • [8] A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
    de Marinis, Filippo
    Atmaca, Akin
    Tiseo, Marcello
    Giuffreda, Libero
    Rossi, Antonio
    Gebbia, Vittorio
    D'Antonio, Chiara
    Dal Zotto, Laura
    Al-Batran, Salah-Eddin
    Marsoni, Silvia
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1091 - 1094
  • [9] The novel potent pan-deacetylase (DAC) inhibitor, panobinostat (LBH589), markedly enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Campbell, Richard A.
    Sanchez, Eric
    Steinberg, Jeffrey
    Share, Michael
    Wang, Joseph
    Li, Mingjie
    Chen, Haiming
    Shalitin, Dror
    Pang, Shen
    Said, Jonathan
    Berenson, James R.
    BLOOD, 2007, 110 (11) : 743A - 743A
  • [10] A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma.
    Wolf, Jeffrey Lee
    Siegel, David
    Matous, Jeffrey
    Lonial, Sagar
    Goldschmidt, Hartmut
    Schmitt, Stefan
    Vij, Ravi
    De Malgalhaes-Silverman, Margarida
    Abonour, Rafat
    Jalaluddin, Muhammad
    Li, Martha
    Hazell, Katharine
    Bourquelot, Priscille M.
    Mateos, Maria-Victoria
    Anderson, Kenneth C.
    Spencer, Andrew
    Harousseau, Jean-Luc
    Blade, Joan
    BLOOD, 2008, 112 (11) : 957 - 957
12345